WO2012051492A3 - Compounds and methods for inhibiting hiv latency - Google Patents

Compounds and methods for inhibiting hiv latency Download PDF

Info

Publication number
WO2012051492A3
WO2012051492A3 PCT/US2011/056284 US2011056284W WO2012051492A3 WO 2012051492 A3 WO2012051492 A3 WO 2012051492A3 US 2011056284 W US2011056284 W US 2011056284W WO 2012051492 A3 WO2012051492 A3 WO 2012051492A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
methods
compounds
inhibiting hiv
hiv latency
Prior art date
Application number
PCT/US2011/056284
Other languages
French (fr)
Other versions
WO2012051492A2 (en
Inventor
Jonathan Karn
Julia Friedman
David C.K. Chu
Original Assignee
University Of Georgia Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Georgia Research Foundation, Inc. filed Critical University Of Georgia Research Foundation, Inc.
Publication of WO2012051492A2 publication Critical patent/WO2012051492A2/en
Publication of WO2012051492A3 publication Critical patent/WO2012051492A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to inhibitors of histone mefhyltransferase, especially nucleoside analogs alone or in combination with additional anti-HIV agents for use in the treatment or prophylaxis of HIV, HIV latency, HIV proviruses and in particular to inhibit, reduce and/or abolish the latent HIV reservoir (latent HIV) in a patient infected with HIV, among other methods.
PCT/US2011/056284 2010-10-14 2011-10-14 Compounds and methods for inhibiting hiv latency WO2012051492A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39308310P 2010-10-14 2010-10-14
US61/393,083 2010-10-14

Publications (2)

Publication Number Publication Date
WO2012051492A2 WO2012051492A2 (en) 2012-04-19
WO2012051492A3 true WO2012051492A3 (en) 2012-07-19

Family

ID=45938987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/056284 WO2012051492A2 (en) 2010-10-14 2011-10-14 Compounds and methods for inhibiting hiv latency

Country Status (1)

Country Link
WO (1) WO2012051492A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
IN2014KN02774A (en) 2012-06-06 2015-05-08 Bionor Immuno As
US9889180B2 (en) 2012-11-19 2018-02-13 Agency For Science, Technology And Research Method of treating cancer
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US20170165321A1 (en) 2014-07-11 2017-06-15 Bionor Immuno As Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
EP3206751A4 (en) 2014-10-14 2018-06-13 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
EP3271020B1 (en) * 2015-03-18 2020-11-25 Vitalant Reversal of latency of retroviruses with a galectin protein
WO2016178987A2 (en) * 2015-05-01 2016-11-10 The United States Of America, As Represented By The Secretary., Department Of Health And Human Services Preventing or treating viral infection by inhibition of the histone methyltransferase ezh1 or ezh2
WO2016177833A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
US20180214519A1 (en) * 2015-07-24 2018-08-02 Constellation Pharmaceuticals, Inc. Combination therapies for modulation of histone methyl modifying enzymes
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
KR20190058477A (en) 2016-08-17 2019-05-29 솔스티스 바이올로직스, 리미티드 Polynucleotide construct
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
AU2019312416A1 (en) 2018-07-27 2021-02-11 Evopoint Biosciences Co., Ltd. Polysubstituted benzene compound and preparation method and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
WO2008001391A2 (en) * 2006-06-27 2008-01-03 Jawaharlal Nehru Centre For Advanced Scientific Research Site-specific inhibitors of histone methyltransferase [hmtase] and process of preparation thereof
US20100166806A1 (en) * 2008-12-29 2010-07-01 Aphios Corporation Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
WO2008001391A2 (en) * 2006-06-27 2008-01-03 Jawaharlal Nehru Centre For Advanced Scientific Research Site-specific inhibitors of histone methyltransferase [hmtase] and process of preparation thereof
US20100166806A1 (en) * 2008-12-29 2010-07-01 Aphios Corporation Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURPHY, R. ET AL.: "Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals", ANTIVIRAL THERAPY, vol. 15, no. 2, 1 April 2010 (2010-04-01), pages 185 - 192 *

Also Published As

Publication number Publication date
WO2012051492A2 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
WO2012051492A3 (en) Compounds and methods for inhibiting hiv latency
PH12018502489A1 (en) Antiviral therapy
CY1118774T1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A NON-NUCLEOID REVERSE TRANSFER INFLUENCE
MX2013005478A (en) Antiviral condensed heterocyclic compounds.
MA39092A1 (en) Pyrrolo [2,3-d] pyrimidinyl, pyrrolo [2,3-b] pyrazinyl and pyrollo [2,3-d] pyridinyl acrylamides
JO3452B1 (en) Aminoheteroaryl benzamides as kinase inhibitors
EA201492204A1 (en) NUCLEOSIDES BASED ON URACIL AND SPIROOXETANE
MD20150043A2 (en) Inhibitors of histone demethylases
EA201390885A1 (en) AZAINDOLS AS ANTI-VIRAL AGENTS AGAINST THE RESPIRATORY SYNCTIAL VIRUS
EA201390794A1 (en) BICYCLIC COMPOUND
AR099632A1 (en) TREATMENT OF A VIRAL INFECTION OF HEPATITIS C, THAT USES A COMBINATION OF COMPOUNDS
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
PH12015501156A1 (en) Pharmaceutical compositions
EA201390198A1 (en) Heterocyclic Compound
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2013185764A3 (en) Pharmaceutical compositions for combination therapy
EA201590364A1 (en) APPLICATION OF AIRWAY PERSON, HIS SALTS AND CRYSTALLINE FORMS AND COMPOSITIONS, ITS CONTAINING, FOR THE TREATMENT OF ZUD
MX343689B (en) Darunavir combination formulations.
EA201490223A1 (en) COMPOSITIONS BASED ON DARUNAVIR
PH12014501140B1 (en) Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder
EA201491532A1 (en) PHARMACEUTICAL COMPOSITIONS FOR USE IN COMPLEX THERAPY
BR112014003989A2 (en) compound, compositions and methods for inhibiting hiv-1 replication in a patient, for treating HIV-infected patients and for pre-exposure prophylaxis for treating the patient and for preventing transmission from infected to uninfected person
EA201500366A1 (en) APPLICATION OF 1-ADAMANTYLETYLOXY-3-MORFOLINO-2-PROPANOL OR ITS PHARMACEUTICALLY ADOPTABLE SALTS IN PHARMACEUTICAL COMPOSITIONS AS A NEURORTHINOPROTECTOR
WO2012016314A9 (en) Arachidonic acid-derived coxib analogue-substituted compounds for use in treating pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11833458

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11833458

Country of ref document: EP

Kind code of ref document: A2